Genferon light (suppositories, 10 pcs., 125000+0.005 IU+g) - price, buy online in Moscow, description, order with delivery to the pharmacy

Genferon light Suppositories, 10 pcs, 125000+0.005 IU+g

Directions for use and doses

The drug can be used both vaginally and rectally.
The route of administration, dose and course duration depend on age and the specific clinical situation. In adults and children over 7 years of age, Genferon Light is used in a dose of 250,000 IU of interferon alfa-2b per suppository. In children under 7 years of age, including infants, it is safe to use the drug at a dose of 125,000 IU of interferon alfa-2b per suppository. In women who are 13-40 weeks pregnant, the drug is used at a dose of 250,000 IU of interferon alfa-2b per suppository. Recommended doses and treatment regimens:

● Acute respiratory viral infections and other acute diseases of a viral nature in children: 1 suppository rectally 2 times a day with a 12-hour interval parallel to the main therapy for 5 days. If, after a 5-day treatment period, the symptoms of the disease do not decrease or become more pronounced, the patient should consult a doctor. According to clinical indications, it is possible to repeat the course of treatment after a 5-day interval.

● Acute respiratory viral infections in frequently and long-term ill children aged 3 to 6 years: 1 suppository (125,000 IU) rectally 2 times a day with an interval of 12 hours for 10 days parallel to standard therapy. After completing the main period of treatment for an acute respiratory viral infection, it is possible to switch to a prophylactic regimen: 1 suppository (125,000 IU) rectally 1 time at night, every other day for 3 weeks.

● Chronic infectious and inflammatory diseases of viral etiology in children over 7 years of age: 1 suppository (250,000 IU) rectally 2 times a day with a 12-hour interval parallel to standard therapy for 10 days. Then for 1-3 months - 1 suppository rectally at night every other day.

● Acute infectious and inflammatory diseases of the urogenital tract in children: 1 suppository rectally 2 times a day with a 12-hour interval for 10 days against the background of specific therapy prescribed and supervised by a doctor.

● Infectious and inflammatory diseases of the urogenital tract in pregnant women: 1 suppository (250,000 IU) vaginally 2 times a day with a 12-hour interval for 10 days against the background of specific therapy prescribed and supervised by a doctor.

● Infectious and inflammatory diseases of the urogenital tract in women: 1 suppository (250,000 IU) vaginally or rectally (depending on the nature of the disease) 2 times a day with a 12-hour interval for 10 days against the background of specific therapy prescribed and supervised by a doctor. For prolonged forms, 1 suppository 3 times a week, every other day, for 1-3 months.

Buy Genferon light vaginal/rectal suppositories 125t IU No. 10 in pharmacies

Genferon Light Buy Genferon Light in pharmacies

DOSAGE FORMS suppositories for vaginal or rectal administration 125000IU+5mg

MANUFACTURERS Biocad CJSC (Russia)

GROUP Antiviral - interferons

COMPOSITION Interferon alpha-2b, taurine.

INTERNATIONAL NON-PROPENTED NAME Interferon alpha-2b+Taurine

PHARMACOLOGICAL ACTION Has local and systemic effects. The drug contains recombinant human interferon alpha-2b. Interferon alpha-2b has antiviral, immunomodulatory, antiproliferative and antibacterial effects. The immunomodulatory effect is manifested, first of all, by enhancing cell-mediated reactions of the immune system, which increases the effectiveness of the immune response against viruses, intracellular parasites and cells that have undergone tumor transformation. Activation under the influence of interferon of leukocytes contained in all layers of the mucous membrane ensures their active participation in the elimination of pathological foci; in addition, due to the influence of interferon, restoration of the production of secretory immunoglobulin A is achieved. The antibacterial effect is mediated by reactions of the immune system, enhanced under the influence of interferon. Taurine helps normalize metabolic processes and tissue regeneration, has membrane-stabilizing and immunomodulatory effects. Taurine helps maintain the biological activity of interferon, enhancing the therapeutic effect of the drug. With rectal administration of the drug, high bioavailability of interferon is observed, and therefore both local and pronounced systemic immunomodulatory effects are achieved; when used intravaginally, due to the high concentration at the site of infection and fixation on the cells of the mucous membrane, a pronounced local antiviral, antiproliferative and antibacterial effect is achieved, while the systemic effect is insignificant due to the low absorption capacity of the vaginal mucosa. The maximum concentration of interferon in the blood serum is achieved 5 hours after administration of the drug. The main route of elimination of β-interferon is renal catabolism. The half-life is 12 hours, which necessitates the use of the drug 2 times a day.

INDICATIONS FOR USE For the treatment of infectious and inflammatory diseases of the urogenital tract in children and women, including pregnant women. As a component of complex therapy - for the treatment of other infectious diseases of viral etiology.

CONTRAINDICATIONS Individual intolerance to interferon and other substances included in the drug. With caution: Exacerbation of allergic and autoimmune diseases. Use during pregnancy and lactation: Clinical studies have proven the effectiveness and safety of using the drug in the second and third trimesters of pregnancy. The safety of using the drug in the first trimester of pregnancy has not been studied.

SIDE EFFECTS Local allergic reactions (itching and burning sensation in the vagina). These phenomena are reversible and disappear within 72 hours after cessation of administration. Continuation of treatment is possible after consultation with a doctor. Phenomena that occur with the use of all types of interferon alfa-2b may be observed, such as chills, fever, fatigue, loss of appetite, muscle and headaches, joint pain, sweating, as well as leukemia and thrombocytopenia. In these cases, it is recommended to consult your doctor to decide whether to discontinue the drug or reduce the dose.

INTERACTION The drug is most effective as a component of complex therapy. When combined with antibacterial, fungicidal and antiviral drugs, mutual potentiation of action is observed, which makes it possible to achieve a high total therapeutic effect

METHOD OF APPLICATION AND DOSAGE The drug can be used both vaginally and rectally. The method of administration, dosage and course duration depend on age, the specific clinical situation and are determined by the attending physician.

OVERDOSE In case of accidental simultaneous administration of more suppositories than prescribed by the doctor, further administration should be suspended for 24 hours, after which treatment can be resumed according to the prescribed regimen.

SPECIAL INSTRUCTIONS The drug does not affect the performance of potentially hazardous activities that require special attention and quick reactions (driving vehicles, machinery, etc.).

STORAGE CONDITIONS Store at a temperature of 2 to 8 degrees. C. Keep out of the reach of children.

Instructions for use GENFERON® (GENFERON)

A combined drug whose effect is determined by the components included in its composition. Has local and systemic effects.

The composition of the drug Genferon® includes recombinant human interferon alpha-2b, produced by a strain of the bacterium Escherichia coli, into which the human interferon alpha-2b gene was introduced using genetic engineering methods.

Interferon alpha-2b has antiviral, immunomodulatory, antiproliferative and antibacterial effects. The antiviral effect is mediated by the activation of a number of intracellular enzymes that inhibit viral replication. The immunomodulatory effect is manifested, first of all, by enhancing cell-mediated reactions of the immune system, which increases the effectiveness of the immune response against viruses, intracellular parasites and cells that have undergone tumor transformation. This is achieved through the activation of CD8+ T killer cells, NK cells (natural killer cells), increased differentiation of B lymphocytes and their production of antibodies, activation of the monocyte-macrophage system and phagocytosis, as well as increased expression of molecules of the major histocompatibility complex type I, which increases the likelihood recognition of infected cells by cells of the immune system. Activation under the influence of interferon of leukocytes contained in all layers of the mucous membrane ensures their active participation in the elimination of pathological foci; in addition, due to the influence of interferon, restoration of the production of secretory immunoglobulin A is achieved. The antibacterial effect is mediated by reactions of the immune system, enhanced under the influence of interferon.

Taurine helps normalize metabolic processes and tissue regeneration, has membrane-stabilizing and immunomodulatory effects. Being a strong antioxidant, taurine directly interacts with reactive oxygen species, the excessive accumulation of which contributes to the development of pathological processes. Taurine helps maintain the biological activity of interferon, enhancing the therapeutic effect of the drug. Benzocaine (anesthetic) is a local anesthetic. Reduces the permeability of the cell membrane to sodium ions, displaces calcium ions from receptors located on the inner surface of the membrane, and blocks the conduction of nerve impulses. Prevents the occurrence of pain impulses at the endings of sensory nerves and their conduction along nerve fibers. It has an exclusively local effect, without being absorbed into the systemic circulation.

Genferon Light, 10 pcs., 250,000 IU+5 mg, vaginal and rectal suppositories

Vaginal or rectal suppositories:
vaginal, rectal.
The route of administration, dosage and course duration depend on age and the specific clinical situation. In adults and children over 7 years of age, Genferon® Light is used in a dosage of 250,000 IU of interferon alfa-2b per suppository. In children under 7 years of age, including infants, it is safe to use the drug at a dosage of 125,000 IU of interferon alfa-2b per suppository. In women who are 13–40 weeks pregnant, the drug is used at a dose of 250,000 IU of interferon alfa-2b per suppository.

Recommended dosages and treatment regimens

ARVI and other acute viral diseases in children:

1 sup. rectally 2 times a day with a 12-hour interval in parallel with the main therapy for 5 days. If, after a 5-day treatment period, the symptoms of the disease do not decrease or become more pronounced, the patient should consult a doctor. According to clinical indications, it is possible to repeat the course of treatment after a 5-day interval.

Chronic infectious and inflammatory diseases of viral etiology in children:

1 sup. rectally 2 times a day with a 12-hour interval simultaneously with standard therapy for 10 days. Then for 1–3 months - 1 sup. rectally at night every other day.

Acute infectious and inflammatory diseases of the urogenital tract in children:

1 sup. rectally 2 times a day with a 12-hour interval for 10 days, against the background of specific therapy prescribed and supervised by a doctor.

Infectious and inflammatory diseases of the urogenital tract in pregnant women:

1 sup. (250,000 IU) vaginally 2 times a day with a 12-hour interval for 10 days, against the background of specific therapy prescribed and supervised by a doctor.

Infectious and inflammatory diseases of the urogenital tract in women:

1 sup. (250,000 IU) vaginally or rectally (depending on the nature of the disease) 2 times a day with a 12-hour interval for 10 days, against the background of specific therapy prescribed and supervised by a doctor. For prolonged forms, 3 times a week every other day, 1 sup. within 1–3 months.

Dosed nasal spray:
intranasally,
by aerosol administration of 1 dose (1 dose = 1 short press on the dispenser).

At the first signs of the disease, Genferon® Light is administered intranasally for 5 days, one dose (one press on the dispenser) into each nasal passage 3 times a day (one dose is approximately 50,000 IU of interferon alfa-2b, the daily dose should not exceed 500,000 IU).

In case of contact with a patient with acute respiratory viral infection and/or hypothermia, the drug is administered according to the indicated regimen 2 times a day for 5–7 days. If necessary, preventive courses are repeated.

Instructions for use of the spray

1. Remove the protective cap.

2. Before using for the first time, press the dispenser several times until a thin stream appears.

3. When using, keep the bottle in an upright position.

4. Inject the drug by pressing the dispenser once into each nasal passage in turn.

5. After use, close the dispenser with the protective cap.

To avoid the spread of infection, individual use is recommended.

Genferon Light suppositories vag/rect 125 thousand IU No. 10

Compound

Active ingredients: interferon alpha-2b - 125,000 IU, taurine - 0.005 g. Excipients: "hard fat", dextran 60000, macrogol 1500, polysorbate 80, T2 emulsifier, sodium hydrogen citrate, citric acid, purified water - sufficient amount until obtained suppository weighing 0.8 g.

Pharmacokinetics

With rectal administration of the drug, high bioavailability (more than 80%) of interferon is observed, and therefore both local and pronounced systemic immunomodulatory effects are achieved; when used intravaginally, due to the high concentration at the site of infection and fixation on the cells of the mucous membrane, a pronounced local antiviral, antiproliferative and antibacterial effect is achieved, while the systemic effect is insignificant due to the low absorption capacity of the vaginal mucosa.

The maximum concentration of interferon in the blood serum is achieved 5 hours after administration of the drug.

The main route of excretion of α-interferon is renal catabolism. The half-life is 12 hours, which necessitates the use of the drug 2 times a day.

Indications for use

As a component of complex therapy - for the treatment of acute respiratory viral infections and other infectious diseases of bacterial and viral etiology in children.
As a component of complex therapy - for the treatment and prevention of repeated episodes of acute respiratory viral infections in frequently and long-term ill children aged 3 to 6 years.
For the treatment of infectious and inflammatory diseases of the urogenital tract in children and women, including pregnant women, against the background of specific therapy prescribed and supervised by a doctor.

Contraindications

individual intolerance to interferon and other substances included in the drug;
1st trimester of pregnancy.

With caution: exacerbation of allergic and autoimmune diseases.

Directions for use and doses

The drug can be used both vaginally and rectally.

The route of administration, dose and course duration depend on age and the specific clinical situation.

In adults and children over 7 years of age, Genferon® Light is used in a dose of 250,000 IU interferon alfa-2b per suppository.
In children under 7 years of age, including infants, it is safe to use the drug at a dose of 125,000 IU interferon alfa-2b per suppository.
In women who are 13-40 weeks pregnant, the drug is used at a dose of 250,000 IU interferon alfa-2b per suppository.

Recommended doses and treatment regimens:

Acute respiratory viral infections and other acute diseases of a viral nature in children: 1 suppository rectally 2 times a day with a 12-hour interval parallel to the main therapy for 5 days. If, after a 5-day treatment period, the symptoms of the disease do not decrease or become more pronounced, the patient should consult a doctor. According to clinical indications, it is possible to repeat the course of treatment after a 5-day interval.
Acute respiratory viral infections in frequently and long-term ill children aged 3 to 6 years: 1 suppository (125,000 IU) rectally 2 times a day with an interval of 12 hours for 10 days in parallel with standard therapy. After completing the main period of treatment for an acute respiratory viral infection, it is possible to switch to a prophylactic regimen: 1 suppository (125,000 IU) rectally 1 time at night, every other day for 3 weeks.
Chronic infectious and inflammatory diseases of viral etiology in children over 7 years of age: 1 suppository (250,000 IU) rectally 2 times a day with a 12-hour interval parallel to standard therapy for 10 days. Then for 1-3 months - 1 suppository rectally at night every other day.
Acute infectious and inflammatory diseases of the urogenital tract in children: 1 suppository rectally 2 times a day with a 12-hour interval for 10 days against the background of specific therapy prescribed and supervised by a doctor.
Infectious and inflammatory diseases of the urogenital tract in pregnant women: 1 suppository (250,000 IU) vaginally 2 times a day with a 12-hour interval for 10 days against the background of specific therapy prescribed and supervised by a doctor.
Infectious and inflammatory diseases of the urogenital tract in women: 1 suppository (250,000 IU) vaginally or rectally (depending on the nature of the disease) 2 times a day with a 12-hour interval for 10 days against the background of specific therapy prescribed and supervised by a doctor. For prolonged forms, 1 suppository 3 times a week, every other day, for 1-3 months.

Storage conditions

At temperatures from 2°C. up to 8°C. Keep out of the reach of children.

Best before date

2 years. Do not use after the expiration date stated on the package.

Description

Interferon. Immunomodulatory drug with antiviral effect.

Dosage form

White or white with a yellowish tint, cylindrical suppositories with a pointed end are uniform in longitudinal section. An air rod or funnel-shaped depression is allowed on the cut.

Pharmacodynamics

GENFERON® LIGHT is a combination drug, the effect of which is determined by the components included in its composition. Has local and systemic effects.

The composition of the drug Genferon® Light includes recombinant human interferon alpha-2b, produced by a strain of the bacterium Escherichia coli, into which the human interferon alpha-2b gene was introduced using genetic engineering methods.

Interferon alpha-2b has antiviral, immunomodulatory, antiproliferative and antibacterial effects.

The antiviral effect is mediated by the activation of a number of intracellular enzymes that inhibit viral replication.

The immunomodulatory effect is manifested, first of all, by enhancing cell-mediated reactions of the immune system, which increases the effectiveness of the immune response against viruses, intracellular parasites and cells that have undergone tumor transformation. This is achieved through the activation of CD8+ T killer cells, NK cells (natural killer cells), increased differentiation of B lymphocytes and their production of antibodies, activation of the monocyte-macrophage system and phagocytosis, as well as increased expression of molecules of the major histocompatibility complex type I, which increases the likelihood recognition of infected cells by cells of the immune system. Activation under the influence of interferon of leukocytes contained in all layers of the mucous membrane ensures their active participation in the elimination of pathological foci; in addition, due to the influence of interferon, the production of secretory immunoglobulin A is restored.

The antibacterial effect is mediated by immune system reactions enhanced by interferon.

Side effects

The drug is well tolerated by patients. Local allergic reactions (itching and burning sensation in the vagina) are possible. These phenomena are reversible and disappear within 72 hours after cessation of administration. Continuation of treatment is possible after consultation with a doctor.

To date, no severe or life-threatening side effects have been observed. Phenomena that occur with the use of all types of interferon alfa-2b, such as chills, fever, fatigue, loss of appetite, muscle and headaches, joint pain, sweating, as well as leukemia and thrombocytopenia, may be observed, but they occur more often when exceeding daily dose over 10,000,000 IU. In these cases, it is recommended to consult your doctor to decide whether to discontinue the drug or reduce the dose.

As with any other interferon alpha drug, and in case of fever after its administration, a single dose of paracetamol is possible in a dose of 500-1000 mg for adults and 250 mg for children.

Use during pregnancy and breastfeeding

Clinical studies have proven the effectiveness and safety of using the drug Genferon® Light in women who are 13-40 weeks pregnant. Use in the first trimester of pregnancy is contraindicated.

There are no restrictions for use during lactation.

Use as directed by a doctor.

Interaction

Genferon® Light is most effective as a component of complex therapy.

When combined with antibacterial, fungicidal and antiviral drugs, mutual potentiation of action is observed, which makes it possible to achieve a high total therapeutic effect.

Overdose

Cases of overdose of Genferon® Light have not been registered. If you accidentally administer more suppositories at a time than were prescribed by your doctor, further administration should be suspended for 24 hours, after which treatment can be resumed according to the prescribed regimen.

Impact on the ability to drive vehicles and operate machinery

Genferon® Light does not affect the performance of potentially hazardous activities that require special attention and quick reactions (driving vehicles, machinery, etc.).